ライフサイエンスコーパス: biguanide

1 nificantly lower than that induced by either biguanide.

2 and enable the rational design of medicinal biguanides.

3 pid biosynthesis in the favorable effects of biguanides.

4 Serine synthesis was not inhibited by biguanides.

5 K) is known to be a major cellular target of biguanides.

6 ga officinalis L.) led to the development of biguanides.

7 osphorylation are regulated independently by biguanides.

8 eated to determine whether polyhexamethylene biguanide, 0.02%, chlorhexidine digluconate, 0.02%, hexa

9 The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.

10 Our data provide a structural basis for biguanide action and enable the rational design of medic

11 vide a mechanism of tumor cell resistance to biguanide activity.

12 ed drugs (insulins, sulfonylureas, glinides, biguanides, alpha-glucosidase inhibitors, thiazolidinedi

13 We now report that novel biguanide and bisguanidine polyamine analogues are poten

14 s, C-fiber responses to injections of phenyl biguanide and lactic acid and to constant-pressure lung

15 The biguanide and ursodeoxycholic acid dual-modified multifu

16 IgE to the biguanide and/or hexamethylene structure was investigate

17 All patients were treated with biguanides and/or diamidines or azoles without resolutio

18 pharmaceutical compounds (Metformin, Phenyl biguanide, and Phenformin) of varied hydrophilicity, dis

19 ent, local irrigation with polyhexamethylene biguanide, and the systemic administration of voriconazo

20 , azines, amidines, guanidines, vinamidines, biguanides, and phosphazenes.

21 tions, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.

22 We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are p

23 nistic activity of an unprecedented class of biguanide-antibiotic conjugates.

24 These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when

25 Biguanides are a class of antidiabetic drugs that includ

26 ord and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse

27 anipulation that can enhance the efficacy of biguanides as antineoplastic agents that target cancer c

28 gagement at vancomycin binding sites through biguanide association with relevant cell-surface anions

29 However, a better understanding of how these biguanides behave as antitumor agents is needed to guide

30 ret these data to explain the selectivity of biguanide binding to different enzyme states.

31 Polyhexamethylene biguanide can inhibit PCR, and we suggest that specimen

32 Phenformin is a drug in the biguanide class that was previously used to treat type 2

33 Metformin, a biguanide commonly used to treat type 2 diabetes, has be

34 ty of structurally matched Re/(99m)Tc(CO)(3)-biguanide complexes as a new class of theranostic pairs.

35 have investigated the effects of the diamino biguanide compound metformin and of hyperglycemia on MG

36 Bacillus subtilis , to develop guanidine and biguanide compounds with up to 20-fold increased potency

37 ese results suggest that cellular effects of biguanides depend on their metal-binding properties.

38 ed us to identify an anti-cancer drug of bis-biguanide dihydrochloride (BBD) as potent anti-mycobacte

39 2 diabetes, the mechanisms of action of the biguanide drug metformin are still being discovered.

40 The biguanide drug metformin has recently been found to impr

41 The biguanide drug metformin is widely prescribed to treat t

42 The biguanide drug metformin stimulates AMP-activated protei

43 Thiazolidinedione and biguanide drugs, which are used to increase insulin sens

44 r cell lines, the global metabolic impact of biguanides during the process of neoplastic transformati

45 Metformin, an insulin-sensitizing biguanide, enhances peripheral insulin action and lowers

46 These include biguanides, glucagon-like peptide 1 receptor (GLP-1) ago

47 Metformin (MF), a member of the biguanide group, has been shown to facilitate osteoblast

48 he delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity of PEI

49 In contrast, in breast CSCs, biguanides have a modest effect on glycolytic and TCA cy

50 Despite of their plant origin, biguanides have not been reported in plants.

51 E reactivity to PHMB as surrogate marker for biguanide/hexamethylene reactivity was detected in 5/32

52 g) or the 5-HT(3) agonist l-(m-chlorophenyl)-biguanide hydrochloride (mCPBG; 5.0-15.0 mg/kg), alone o

53 hat the recent evolution of metforminase and biguanide hydrolase enzymes allow Pseudomonads to conver

54 Although phenformin is the more potent biguanide in both systems, the metabolic profiles of the

55 ddition, the possible biosynthetic routes of biguanide in these plant foods are discussed.

56 facilitate studies on metformin and related biguanides in cancer prevention and treatment.

57 d to increased interest in possible roles of biguanides in cancer prevention and/or treatment.

58 The molecular mode of action of biguanides, including the drug metformin, which is widel

59 Biguanides, including the world's most prescribed drug f

60 ular depletion of aPKC (>90%) led to loss in biguanide-induced aPKC phosphorylation, it had no effect

61 for serine to allow cells to compensate for biguanide-induced decrease in oxidative phosphorylation

62 ional PKCs caused a significant reduction in biguanide-induced GU.

63 Biguanide-induced inactivation of mTORC1 subsequently in

64 We demonstrate that biguanides inhibit growth by inhibiting mitochondrial re

65 c profiles are consistent with the idea that biguanides inhibit mitochondrial complex 1, but they ind

66 Metformin (MF), a second-generation biguanide, is a commonly used oral antidiabetic drug tha

67 tochondrial oxidative phosphorylation (using biguanides) led to a complex response that could improve

68 he 5-HT3 receptor agonist 1-m-(chlorophenyl) biguanide (m-CPGB, 1 microM), markedly increased (300%)

69 Biguanide may arise through successive N-demethylations

70 Biguanides may exploit specific metabolic vulnerabilitie

71 been proposed that this compound or related biguanides may have antineoplastic activity.

72 by the selective agonist 1-(m-chlorophenyl)-biguanide (mCPBG).

73 d the 5-HT3 receptor agonist, m-chlorophenyl-biguanide (mCPBG; 250, 500, or 1000 ng).

74 % [14 of 15 isolates]) and polyhexamethylene biguanide (median growth grade, 0.0; kill incidence rate

75 Biguanide/metal interactions are stabilized by extensive

76 CT1) affects the response to the widely used biguanide metformin (see the related article beginning o

77 onse to the sulphonylurea gliclazide and the biguanide metformin differed in HNF-1alpha diabetes and

78 The biguanide metformin had no effect on either enzyme, wher

79 In recent decades, the antihyperglycemic biguanide metformin has been used extensively in the tre

80 ion between TEA and Arg was found, while the biguanide metformin was able to strongly inhibit uptake

81 Use of the biguanide metformin, an AMPK activator, is associated wi

82 AMPK activators, including the antidiabetic biguanide metformin, inhibited FXR agonist induction of

83 IgE-reactivities with the biguanide or hexamethylene components of other disinfect

84 The biguanide phenformin has been shown to independently dec

85 tabolic effects of metformin and the related biguanide phenformin have been investigated in establish

86 ation of the ERK inhibitor SCH772984 and the biguanide phenformin.

87 counterparts that are more sensitive to the biguanide phenformin.

88 Met and its related biguanide, phenformin, stimulated AMPK activation/phosph

89 Polyhexamethylene biguanide (PHMB) is a cationic antimicrobial polymer wit

90 Polyhexamethylene biguanide (PHMB) is a disinfectant used in swimming pool

91 widely used antimicrobial polyhexamethylene biguanide (PHMB) kills bacteria selectively over host ce

92 ith CHX like polyhexanide (polyhexamethylene biguanide; PHMB), alexidine (ALX), or octenidine (OCT),

93 lyethyleneimine (PEI) and poly(hexamethylene biguanide) (PHMBG) and are prepared by a two-step proced

94 cal laboratory models have demonstrated that biguanides possess antitumor activities that suggest the

95 f chemosensitive vagal afferents with phenyl biguanide produced an increase (n=3), decrease (n=2), or

96 We demonstrate that biguanides prompt lifespan extension by stimulating ethe

97 A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine W

98 The objective of this study was to quantify biguanide related compounds (BRCs) in experimentally or

99 Nonetheless, the mechanism of action of biguanides remains imperfectly understood.

100 lating activity, and then review progress on biguanide repurposing in cancer therapeutics and the pos

101 Notably, the biguanide sensitivity of cancer cells with mtDNA mutatio

102 nabinoid-1 receptor (CB(1)R) with a built-in biguanide sensor to mimic 5'-adenosine monophosphate kin

103 et-induced AMPK signaling but only repressed biguanide-stimulated GU by approximately 20%.

104 tineoplastic effects of phenformin (a potent biguanide structurally related to metformin).

105 ication of the metal-liganding groups of the biguanide structure, supporting recent data that AMPK an

106 Biguanides such as metformin are widely used worldwide f

107 Biguanides such as metformin have previously been shown

108 Biguanides, such as the diabetes therapeutics metformin

109 Biguanides, such as the diabetes therapeutics metformin

110 Our isolated Pseudomonads also grow on biguanide, suggesting the existence of an additional bre

111 Although biguanides, sulfonylurea, glitazones, and dipeptidyl pep

112 d pressure, statins adjusted for lipids, and biguanides, sulfonylureas, alpha-glycosidase inhibitors

113 l focused on traditional therapeutic options Biguanides, sulfonylureas, and dipeptidyl peptidase-4 in

114 kers, diuretics, nitrates, statins, insulin, biguanides, sulfonylureas, aspirin, and other nonsteroid

115 eported a series of (bis)guanidines and (bis)biguanides that are potent inhibitors of LSD1 and induce

116 Pseudomonads to convert either metformin or biguanide to guanylurea, which can be assimilated by exi

117 wn to encode an aminohydrolase that converts biguanide to guanylurea.

118 and upregulation of ACAD10 are required for biguanides to reduce viability in melanoma and pancreati

119 vidence that this intrinsic property enables biguanides to regulate AMPK, glucose production, glucone

120 ring the process of cellular transformation, biguanide treatment prevents the boost in glycolytic int

121 anced the tumor growth-inhibitory actions of biguanide treatment.

122 hnicity, diabetes with or without insulin or biguanide use, hypertension, ischemic heart disease, dys

123 Our lead biguanide-vancomycin conjugate, V-C6-Bg-PhCl (5e), induc

124 Polyhexamethylene biguanide was the only topical drug that demonstrated PC

125 in reducing glucose production has been the biguanides, which include phenformin and metformin, the

126 Metformin is a biguanide widely prescribed to treat Type II diabetes th

127 Metformin, a biguanide widely used in the treatment of type II diabet

128 bitory drug-target interaction(s) of a model biguanide with mammalian respiratory complex I by combin